8-K: Altimmune Secures $100 Million Credit Facility with Hercules Capital to Advance Pemvidutide Development

Altimmune has secured a $100 million credit facility with Hercules Capital to support the ongoing development of pemvidutide for liver and cardiometabolic diseases.

Summary

• Altimmune entered into a Loan and Security Agreement with Hercules Capital for up to $100 million in term loans.
• The credit facility will be available in four tranches, with $15 million funded initially on May 13, 2025.
• An additional $25 million is available in 2025, and $60 million is available beginning in 2026, subject to certain milestones and lender approval.
• The term loan matures on June 1, 2029, and bears interest at the greater of prime rate plus 2.45% or a fixed rate that decreases from 9.95% to 9.45% after December 31, 2025.
• The company reported cash, cash equivalents, and short-term investments of $150 million as of March 31, 2025.
• Top-line data from the IMPACT Phase 2b trial of pemvidutide in MASH is expected in Q2 2025.
• Phase 2 trials in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) are expected to initiate in Q2 and Q3 2025, respectively.
• Research and development expenses were $15.8 million for the three months ended March 31, 2025, compared to $21.5 million in the same period in 2024.
• Net loss for the three months ended March 31, 2025, was $19.6 million, or $0.26 net loss per share, compared to a net loss of $24.4 million, or $0.34 net loss per share, in the same period in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company has secured significant funding, is progressing with clinical trials, and has a strong cash position. However, it is still operating at a loss and faces risks associated with clinical development and debt obligations.

Positives

• The $100 million credit facility strengthens Altimmune's balance sheet and provides financial flexibility.
• The credit facility is structured with interest-only payments for up to 42 months upon achievement of milestones.
• The company has a strong cash position of $150 million as of March 31, 2025.
• IND applications for pemvidutide in AUD and ALD have been cleared by the FDA.
• Net loss per share decreased from $0.34 to $0.26 compared to the same period in 2024.

Negatives

• The Loan Agreement includes customary events of default, including payment defaults, breaches of representations and warranties, breaches of covenants following any applicable cure period and the occurrence of certain events that could reasonably be expected to have a material adverse effect as set forth in the Loan Agreement.
• The Loan Agreement includes affirmative and restrictive covenants, including maintenance of a minimum cash, cash equivalents and liquid funds covenant that applies beginning on April 1, 2026.
• The company reported a net loss of $19.6 million for the first quarter of 2025.

Risks

• The availability of subsequent tranches of the credit facility is contingent upon achieving certain clinical and financial milestones and, in some cases, lender approval.
• The Loan Agreement includes customary events of default, which could lead to acceleration of the Term Loan obligations and foreclosure on collateral.
• Clinical trial results may not be favorable, which could impact the development and commercialization of pemvidutide.
• Delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy could impact the company's operations.

Future Outlook

Altimmune anticipates top-line data from the IMPACT Phase 2b trial of pemvidutide in MASH in Q2 2025 and plans to initiate Phase 2 trials in AUD and ALD in Q2 and Q3 2025, respectively. The company expects the credit facility to significantly extend its cash runway.

Management Comments

• Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune, stated that the first quarter of 2025 was productive and that the company is approaching a number of important milestones.
• Dr. Garg believes that achieving statistical significance on MASH resolution and fibrosis improvement at only 24 weeks, coupled with clinically meaningful weight loss, would position pemvidutide as the best-in-class therapeutic candidate for the treatment of MASH.
• Dr. Garg also mentioned the unveiling of two additional indications for pemvidutide in AUD and ALD and the intent to initiate Phase 2 clinical trials in these indications in Q2 and Q3, respectively.
• Adam Soller, Managing Director at Hercules Capital, stated that Hercules is thrilled to support Altimmune as it develops pemvidutide as a potential therapy for the treatment of MASH, AUD and ALD.

Industry Context

Altimmune is focused on developing peptide-based therapeutics for liver and cardiometabolic diseases, an area of significant unmet medical need. The company's lead program, pemvidutide, targets MASH, obesity, AUD, and ALD, which are prevalent and growing health concerns. Securing funding from Hercules Capital, a leader in debt financing for life science companies, positions Altimmune to advance its clinical programs and potentially compete with other companies in the metabolic disease space.

Comparison to Industry Standards

• The document mentions that if successful, pemvidutide would be the first investigational therapy in MASH to achieve statistical significance in both MASH resolution and fibrosis improvement, as well as demonstrate meaningful weight loss, after only 24 weeks of treatment.
• This would position pemvidutide favorably compared to existing treatments and other investigational therapies in development for MASH, such as those from Intercept Pharmaceuticals (OCA), Madrigal Pharmaceuticals (resmetirom), and Viking Therapeutics (VK2809).
• The credit facility from Hercules Capital is a common financing strategy for clinical-stage biopharmaceutical companies, similar to arrangements made by companies like Biohaven Pharmaceuticals and CRISPR Therapeutics to fund their research and development activities.

Stakeholder Impact

• Shareholders will benefit from the strengthened financial position and continued development of pemvidutide.
• Employees will have job security and opportunities for advancement as the company progresses its clinical programs.
• Patients with MASH, AUD, and ALD may benefit from the development of new treatment options.
• Creditors are exposed to the risk of default on the Term Loan obligations.

Next Steps

• Altimmune will continue the IMPACT Phase 2b trial of pemvidutide in MASH.
• The company will initiate Phase 2 trials in AUD and ALD.
• Altimmune will work towards achieving the milestones required to access additional tranches of the credit facility.
• The company will file the Loan Agreement with the SEC in connection with its first quarter 2025 Form 10-Q filing.

Key Dates

Keywords

Altimmune, Pemvidutide, Hercules Capital, MASH, AUD, ALD, Credit Facility, Clinical Trials, Biopharmaceutical, Liver Disease, Cardiometabolic Disease